Intravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer

Stefanie Schmidt, Frank Kunath, Bernadette Coles, Desiree Louise Draeger, Laura Maria Krabbe, Rick Dersch, Katrin Jensen, Philipp Dahm, Joerg J. Meerpohl

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effects of bacillus Calmette-Guérin (BCG) intravesical therapy compared to mitomycin C (MMC) intravesical therapy for treating Ta and T1 bladder cancer in adults.

Original languageEnglish (US)
Article numberCD011935
JournalCochrane Database of Systematic Reviews
Volume2015
Issue number11
DOIs
StatePublished - Nov 5 2015

Bibliographical note

Funding Information:
Rick Dersch: Supported by the Deutsche Gesellschaft für Neurologie (German Academy of Neurology) to conduct systematic reviews.

Fingerprint Dive into the research topics of 'Intravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer'. Together they form a unique fingerprint.

Cite this